Post Marketing Surveillance of Roflumilast in Korea

Study identifier:RO-2455-402-KR

ClinicalTrials.gov identifier:NCT02068456

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Post Marketing Surveillance of Roflumilast in Korea

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

-

Healthy volunteers

No

Study drug

Roflumilast

Sex

All

Actual Enrollment

1837

Study type

Observational

Age

18 Years +

Date

Study Start Date: 18 Sept 2012
Primary Completion Date: 26 Apr 2017
Study Completion Date: 26 Apr 2017

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2017 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria